Effects of Polymorphism of the beta1 Adrenoreceptor and CYP2D6 on the Therapeutic Effects of Metoprolol  

Oleh:

Yuan, H. ; Huang, Z. ; Yang, G. ; Lv, H.

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: The Journal of International Medical Research vol. 36 no. 06 (Nov. 2008), page 1354-1362.
Topik: beta1 Adrenoreceptor; Metoprolol

Ketersediaan

Perpustakaan FK Nomor Panggil: J11.K.2008.02 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Metoprolol is a lipophilic beta1 selective adrenergic receptor antagonist used in antihypertensive therapy. It is metabolized by the protein product of the cytochrome P450 2D6 (CYP2D6) gene. Few studies have been performed on the association between the beta1 adrenoreceptor, CYP2D6 polymorphism and blood pressure. The one reported here is a prospective, observational, clinical study in Chinese Han hypertensive patients on the combined influences of CYP2D6 and beta1 adrenoreceptor polymorphisms on the therapeutic effects of metoprolol in 300 out-patients with essential hypertension. The same dose of metoprolol achieved different therapeutic effects in patients with different CYP2D6 and beta1 adrenoreceptor polymorphisms. Additionally, different doses of metoprolol could achieve the same therapeutic effects in patients with different CYP2D6 and beta1 adrenoreceptor polymorphisms. Knowledge of the combination of CYP2D6 and beta1 adrenoreceptor polymorphisms may be used to guide antihypertensive therapy using beta1 adrenoreceptor antagonists.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali